Related Experiment Video
Updated: May 25, 2026
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Therapeutic approaches to modulating Notch signaling: current challenges and future prospects
1Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Abstract:
Dysregulated Notch signaling has been implicated in numerous human diseases, including a broad spectrum of cancers. Mutations in Notch1 are prevalent in T-cell acute lymphoblastic leukemia, and abnormal expression of different human Notch receptors contributes to B-cell tumors as well as cancers of the breast, lung, pancreas, skin, prostate, colon, brain and other tissues. Several γ-secretase inhibitors, small chemical compounds that were initially developed to inhibit the activity of the γ-secretase aspartyl protease in Alzheimer's disease, are now being explored for their potential chemotherapeutic applications in Notch-associated cancers. An alternative approach involves the development of antibodies to inhibit specific Notch receptors, their activating ligands, or other components of the Notch pathway in tumors. Here we review recent progress and current challenges in the use of these strategies to modulate Notch signaling for cancer therapy.
Insights
Dysregulated Notch signaling drives various cancers. Researchers are exploring γ-secretase inhibitors and antibodies to target Notch pathway components for novel cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Dysregulated Notch signaling is a key factor in the development of various human cancers.
- Notch pathway mutations and abnormal receptor expression are linked to T-cell acute lymphoblastic leukemia and other malignancies, including breast, lung, and prostate cancers.
Purpose of the Study:
- To review current strategies for modulating Notch signaling in cancer therapy.
- To discuss the progress and challenges associated with using γ-secretase inhibitors and antibodies against Notch pathway components.
Main Methods:
- Review of recent scientific literature on Notch signaling in cancer.
- Analysis of therapeutic strategies involving γ-secretase inhibitors and antibodies targeting the Notch pathway.
Main Results:
- γ-secretase inhibitors, initially developed for Alzheimer's disease, show potential in treating Notch-associated cancers.
- Antibody-based approaches targeting Notch receptors or ligands are being developed as alternative cancer therapies.
Conclusions:
- Modulating Notch signaling presents a promising avenue for cancer treatment.
- Further research is needed to overcome challenges and optimize the efficacy of these therapeutic strategies.
Related Concept Videos
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
01:41Non-Canonical Wnt Signaling Pathways
01:41Non-Canonical Wnt Signaling Pathways
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...